Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient

Blood Coagul Fibrinolysis. 2017 Mar;28(2):181-184. doi: 10.1097/MBC.0000000000000547.

Abstract

We present here the first known case of successful immune tolerance induction (ITI) using recombinant factor VIII (rFVIII), turoctocog alfa, in a patient with severe haemophilia A. The 38-year-old patient with a long-standing inhibitor required urgent surgery for severe arthropathy. rFVIII was administered throughout the surgical period. Surgery was considered successful, but on day 7 after surgery, an increased level of FVIII inhibitors were detected. ITI was attempted immediately thereafter according to the Bonn protocol. Inhibitors were no longer detected on day 17; 13 months later, successful ITI was achieved. This case suggests that a long-time interval between inhibitor appearance and the start of ITI therapy may not necessarily indicate poor prognosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Factor VIII / administration & dosage
  • Factor VIII / therapeutic use*
  • Hemophilia A / immunology*
  • Hemostatics
  • Humans
  • Immune Tolerance*
  • Male
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use*

Substances

  • Hemostatics
  • Recombinant Proteins
  • recombinant factor VIII N8
  • Factor VIII